Novartis: new data backs bronchodilator in COPD.
(CercleFinance.com) - Novartis said on Tuesday that new analyses reinforce the potential of Ultibro Breezhaler for chronic obstructive pulmonary disease (COPD) patients who have been treated with steroids in the past.
A study suggests that inhaled corticosteroids may not be needed in some COPD patients with high blood eosinophil (a type of white blood cell) counts, the Swiss biopharmaceutical firm said.
Moreover, the data showed that the company's bronchodilator consistently provided superior or similar benefits over GSK's Seretide in COPD patients regardless of the eosinophil count.
The study involving 3,362 COPD patients is conducted at 356 sites across 43 countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.